Maxim Group analyst Naz Rahman maintained a Buy rating on 9 Meters Biopharma (NMTR – Research Report) yesterday and set a price target of $2.00. The company's shares closed last Thursday at $0.56, close to its 52-week low of $0.51. According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -17.2% and a 21.6% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Neurosense Therapeutics Ltd., and Vertex Pharmaceuticals. Currently, the analyst consensus on 9 Meters Biopharma is a Strong Buy with an average price target of $3.50, which is a 503.
https://www.tipranks.com/news/blurbs/maxim-group-thinks-9-meters-biopharmas-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more 9 Meters Biopharma Charts.
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more 9 Meters Biopharma Charts.